Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.

Calderón-Garcidueñas L, Avila-Ramírez J, Calderón-Garcidueñas A, González-Heredia T, Acuña-Ayala H, Chao CK, Thompson C, Ruiz-Ramos R, Cortés-González V, Martínez-Martínez L, García-Pérez MA, Reis J, Mukherjee PS, Torres-Jardón R, Lachmann I.

J Alzheimers Dis. 2016 Sep 6;54(2):597-613. doi: 10.3233/JAD-160472.

PMID:
27567860
2.

Non-Phosphorylated Tau in Cerebrospinal Fluid is a Marker of Alzheimer's Disease Continuum in Young Urbanites Exposed to Air Pollution.

Calderón-Garcidueñas L, Mukherjee PS, Waniek K, Holzer M, Chao CK, Thompson C, Ruiz-Ramos R, Calderón-Garcidueñas A, Franco-Lira M, Reynoso-Robles R, Gónzalez-Maciel A, Lachmann I.

J Alzheimers Dis. 2018;66(4):1437-1451. doi: 10.3233/JAD-180853.

PMID:
30412505
3.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.

Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.

PMID:
25971633
4.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

5.

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.

Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L.

Alzheimers Res Ther. 2017 Jul 28;9(1):52. doi: 10.1186/s13195-017-0276-4.

6.

Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease.

Calderón-Garcidueñas L, Franco-Lira M, D'Angiulli A, Rodríguez-Díaz J, Blaurock-Busch E, Busch Y, Chao CK, Thompson C, Mukherjee PS, Torres-Jardón R, Perry G.

Environ Res. 2015 Jul;140:579-92. doi: 10.1016/j.envres.2015.05.012. Epub 2015 Jun 1.

PMID:
26037109
7.

Combustion-derived nanoparticles, the neuroenteric system, cervical vagus, hyperphosphorylated alpha synuclein and tau in young Mexico City residents.

Calderón-Garcidueñas L, Reynoso-Robles R, Pérez-Guillé B, Mukherjee PS, Gónzalez-Maciel A.

Environ Res. 2017 Nov;159:186-201. doi: 10.1016/j.envres.2017.08.008. Epub 2017 Aug 10.

PMID:
28803148
8.

Early Alzheimer's and Parkinson's disease pathology in urban children: Friend versus Foe responses--it is time to face the evidence.

Calderón-Garcidueñas L, Franco-Lira M, Mora-Tiscareño A, Medina-Cortina H, Torres-Jardón R, Kavanaugh M.

Biomed Res Int. 2013;2013:161687. doi: 10.1155/2013/161687. Epub 2013 Feb 7. Review.

9.

Combustion-Derived Nanoparticles in Key Brain Target Cells and Organelles in Young Urbanites: Culprit Hidden in Plain Sight in Alzheimer's Disease Development.

González-Maciel A, Reynoso-Robles R, Torres-Jardón R, Mukherjee PS, Calderón-Garcidueñas L.

J Alzheimers Dis. 2017;59(1):189-208. doi: 10.3233/JAD-170012.

PMID:
28598844
10.

Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.

Delgado-Alvarado M, Gago B, Gorostidi A, Jiménez-Urbieta H, Dacosta-Aguayo R, Navalpotro-Gómez I, Ruiz-Martínez J, Bergareche A, Martí-Massó JF, Martínez-Lage P, Izagirre A, Rodríguez-Oroz MC.

Mov Disord. 2017 Jul;32(7):1066-1073. doi: 10.1002/mds.27001. Epub 2017 May 26.

PMID:
28548309
11.

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.

Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J.

Acta Neuropathol. 2013 Nov;126(5):683-97. doi: 10.1007/s00401-013-1148-z. Epub 2013 Jun 29.

12.

CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.

Gao R, Zhang G, Chen X, Yang A, Smith G, Wong DF, Zhou Y.

PLoS One. 2016 Oct 20;11(10):e0164762. doi: 10.1371/journal.pone.0164762. eCollection 2016.

13.

Alzheimer's disease and alpha-synuclein pathology in the olfactory bulbs of infants, children, teens and adults ≤ 40 years in Metropolitan Mexico City. APOE4 carriers at higher risk of suicide accelerate their olfactory bulb pathology.

Calderón-Garcidueñas L, González-Maciel A, Reynoso-Robles R, Kulesza RJ, Mukherjee PS, Torres-Jardón R, Rönkkö T, Doty RL.

Environ Res. 2018 Oct;166:348-362. doi: 10.1016/j.envres.2018.06.027. Epub 2018 Jun 20.

PMID:
29935448
14.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

15.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.

PMID:
21469206
16.
17.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
18.

Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Williams SM, Schulz P, Sierks MR.

Eur J Neurosci. 2016 Jan;43(1):3-16. doi: 10.1111/ejn.13056. Epub 2015 Oct 15.

19.

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.

Hall S, Surova Y, Öhrfelt A; Swedish BioFINDER Study, Blennow K, Zetterberg H, Hansson O.

Mov Disord. 2016 Jun;31(6):898-905. doi: 10.1002/mds.26578. Epub 2016 Feb 16.

20.

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.

Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, Aarsland D, Svenningsson P, Farotti L, Verbeek MM, Schlossmacher MG.

J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10. Review.

Supplemental Content

Support Center